The SANT Committee, the new target of lobbying by the giants of the pharmaceutical industry?
The recent elevation of the European Parliament’s public health committee raises significant concerns regarding potential industry capture. Critics warn that powerful lobbying groups from the pharmaceutical and tobacco sectors may prioritize economic interests over the committee’s core mission of protecting public health. This tension highlights a critical challenge in ensuring that legislative bodies remain focused on patient well-being rather than corporate agendas. Substantial financial resources are being deployed by major companies and their representatives to influence EU policy through lobbying firms and direct meetings. The sheer volume of spending and the high frequency of interactions between industry representatives and key committee members suggest a deep integration of commercial interests into the regulatory process. This dynamic threatens the integrity of policy-making, as opaque lobbying activities can skew legislative priorities away from independent public health assessments. This situation is highly relevant to open data because it underscores the urgent need for transparent, accessible, and standardized lobbying registers. While current disclosure mechanisms exist, they are often voluntary and incomplete, hindering public scrutiny and accountability. Strengthening open data practices in this domain is essential to expose influence campaigns, allowing citizens and watchdogs to verify whether public health policies are being shaped by democratic consensus or by corporate power.
Source: bursa.roPublished on 2024-12-24